Articles On Neuren Pharmaceuticals (ASX:NEU)
Title | Source | Codes | Date |
---|---|---|---|
Healthcare stocks can drive healthy returns
At the $240 million Perennial Better Future Trust, healthcare stocks are a critical component of our ESG-focused portfolio. These stocks, many of which have global reach, have the potential to generate attractive returns while shaping a bet... |
Rask Media | NEU | 5 months ago |
Australian Broker Call *Extra* Edition – Nov 14, 2023
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now... |
FNArena | NEU | 5 months ago |
Neuren Pharmaceuticals completes Phelan-McDermid syndrome Phase 2 trial
Neuren Pharmaceuticals (ASX:NEU) has announced that its Phase 2 clinical trial of NNZ-2591 for Phelan-McDermid syndrome has completed all study visits. |
BiotechDispatch | NEU | 5 months ago |
ScoPo’s (actually Wilkie’s) Powerplays: Yoga = chill. Fact. And ASX health stocks up for second week
ASX health stocks rise in past five days and outpace broader markets Blue chip ResMed slips as US FDA approves weight loss drug Clinical stage immuno-oncology small cap Immutep gains 160% Morgans healthcare and life sciences expert Iain... |
Stockhead | NEU | 5 months ago |
ASX Large Caps: Shares down as RBA graphs inflation path; jobs stock APM plunges 20pc after this warning
ASX erased yesterday’s gains on Fed chair Powell’s hawkish tilt The RBA has revised its inflation target upward Job seekers’ services stock APM was worst large cap after issuing a warning The ASX erased yesterday’s gains, down by -0.5%... |
Stockhead | NEU | 5 months ago |
ASX Large Caps: Xero slumps 13pc, NAB issues a warning, while China is back to deflation
ASX closed modestly higher as stocks were up across the board Xero slumped 13pc, despite delivering strong half-year results Optus CEO can’t explain in layman terms the root cause of yesterday’s outage The ASX rose by 0.2% on Thursday,... |
Stockhead | NEU | 5 months ago |
Here are the top 10 ASX 200 shares today
It was a great start to the trading week this Monday for the S&P/ASX 200 Index (ASX: XJO). After a great week last week, the ASX 200 kept the train rolling dow... |
Motley Fool | NEU | 5 months ago |
ScoPo’s Powerplays: Who fancies 22 minutes of exercise? And ASX health stocks are up (finally)
ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp... |
Stockhead | NEU | 6 months ago |
TMH Market Close: ASX200 finishes higher, led by real estate sector
We’re coming to you from Perth Town Hall, where the Young Investor Carnival has been held today. It’s an event hosted by the Young Investor Circle, to help educate new investors. You can see interviews with some of the panellists in o... |
themarketherald.com.au | NEU | 6 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO)'s so-far lucrative month of November continued this Friday. After banking gains on Wednesday and yesterday, the ASX 200 finishe... |
Motley Fool | NEU | 6 months ago |
ASX Large Caps: Shares 1pc higher as Neuren, Block surge; SBF found guilty of all charges
ASX lifted 1pc on Friday, up 3pc for the week Neuren, Block Inc, Lendlease, and media stocks were the best gainers FTX founder Sam Bankman-Fried found guilty on all charges The ASX tracked Wall Street to close 1% higher today. For the w... |
Stockhead | NEU | 6 months ago |
Neuren Pharmaceuticals to receive significant royalties on back of DAYBUE sales surge
Neuren Pharmaceuticals (ASX: NEU) is expecting to receive increasing royalty payments from its US partner Acadia Pharmaceuticals, with sales of the recently launched DAYBUE treatment continuing to surge. The Australian pharmaceutical compan... |
smallcapsau.mystagingwebsite.com | NEU | 6 months ago |
Why Block, Core Lithium, Neuren, and Tietto shares are charging higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a very positive note. At the time of writing, the benchmark index is up 1.1% to 6,977.1 points. Four ASX shares that are rising more than most today... |
Motley Fool | NEU | 6 months ago |
TMH Market Update: ASX200 up 1.2pc with all sectors in the green
Welcome to our market update, coming to you from the Young Investor Carnival at the Perth Townhall today. The event – held by the organisation, Young Investor Circle, is all about educating those new to investment through panel discussio... |
themarketherald.com.au | NEU | 6 months ago |
Q A: Neurotech’s Dr Thomas Duthy on commercialising NTI164 as a treatment for PANDAS/PANS
Neurotech has a clear path for development and commercialisation of NTI164 to treat PANDAS/PANS With no approved therapy for PANDAS/PANS Neurotech is pursing orphan drug designation for NTI164 Results of Neurotech’s phase 1/2 trial inves... |
Stockhead | NEU | 6 months ago |
ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica 40pc on Alzheimer’s data
Neuren’s blockbuster drug DAYBUE generates big sales in Q3 Argenica jumps 40pc after releasing preclinical results from Alzheimer’s trial Integral Diagnostics crashes 30pc after conceding more inflationary pressures ahead Neuren’s DAYBU... |
Stockhead | NEU | 6 months ago |
Here are the top 10 ASX 200 shares today
In some much-needed relief, the S&P/ASX 200 Index (ASX: XJO) has given investors a big day of relief. By the end of this Tuesday's session, the ASX 200 had shrugge... |
Motley Fool | NEU | 6 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) has once again started the trading week off on the wrong side of the bed. After giving investors relief from the sell-offs we have... |
Motley Fool | NEU | 6 months ago |
Top performing ASX life science companies
ASX-listed Impedimed Limited Pharmaceuticals (ASX:IDP), Avita Medical (ASX:AVH), and Neuren Pharmaceutical (ASX:NEU) lead in share price increase for 2023 while Lumos Diagnostics (ASX: LDX) tops third-quarter rankings. |
BiotechDispatch | NEU | 6 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) had gotten through a bumpy, but overall positive day of trading this Wednesday. After spending time in both positive and negative territory... |
Motley Fool | NEU | 6 months ago |
Dr Boreham’s Crucible: Dimerix has so far proved the doubters wrong. Next stop – the US
Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni... |
Stockhead | NEU | 6 months ago |
Here are the top 10 ASX 200 shares today
It's been yet another pleasing day for the S&P/ASX 200 Index (ASX: XJO) this Wednesday, giving ASX shares a three-for-three winning streak for the week thus far. The ASX 200 put... |
Motley Fool | NEU | 6 months ago |
Why Boss Energy, Meridian Energy, Neuren, and Tyro shares are falling today
The S&P/ASX 200 Index (ASX: XJO) is in fine form on Tuesday. In afternoon trade, the benchmark index is up 1.2% to 7,054.2 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's why they a... |
Motley Fool | NEU | 6 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) has finally cracked its run of negativity and given investors a positive day today. After falling every single day this week thus far, the ASX 200... |
Motley Fool | NEU | 6 months ago |
ASX Large Caps: ASX 200 closes higher – ‘We’re back baby, we’re back’
ASX closes higher as Wall Street rebounds and US bond yields retreat on weaker jobs data Lithium miners fall as J.P. Morgan downgrades sector after reviewing lithium price outlook Life 360 and Xero higher as tech sector rallies along with... |
Stockhead | NEU | 6 months ago |
Bell Potter says these are the best ASX shares to buy in October
If you're in the market for some new ASX shares this month, then it could be worth listening to what analysts at Bell Potter are saying. That's because they have just revealed their favoured picks for October. Two on list this month are... |
Motley Fool | NEU | 6 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) has just endured a horror day as investors scramble for the exits amid widespread fears over ASX sales. By the end of today's trading, the ASX 200 ha... |
Motley Fool | NEU | 7 months ago |
ASX Large Caps: ASX falls 1.28pc to hit 100-day low, RBA keeps rates on hold for now
ASX slips to 100-day low as climbing US 10-year bond yields weigh on global markets RBA keeps rates on hold but new governor Michele Bullock hasn’t ruled out further hikes CSL leads healthcare higher after Morgan Stanley puts an overweigh... |
Stockhead | NEU | 7 months ago |
Dr Boreham’s Crucible: With a US focus, can Next Science’s new leaders stem the bleeding?
With apologies to Charles Dickens, it’s the best of times and the worst of times for wound care house Next Science (ASX:NXS) as it shapes itself up for a renewed market assault under a new CEO. On the positive side of the ledger, the compan... |
Stockhead | NEU | 7 months ago |
Here are the top 10 ASX 200 shares today
It's been yet another day of falls for ASX shares and the S&P/ASX 200 Index (ASX: XJO) this Thursday, making it the third of four days this week that have seen losses. The ASX 200 chec... |
Motley Fool | NEU | 7 months ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) has once again given investors a headache this Wednesday, as the index recorded yet another day in the red. Following yesterday's sell-off, the ASX 200... |
Motley Fool | NEU | 7 months ago |
ScoPo’s Powerplays: Who remembers that time they died? Oh, and Ramsay Healthcare cops credit downgrade
ASX health sector falls in line with broader markets as macroeconomic factors continue to create uncertainty Fitch Ratings Agency downgraded the credit rating of Ramsay Health Care (ASX:RHC) to BBB- from BBB Botanix Pharmaceuticals expects... |
Stockhead | NEU | 7 months ago |
2023 ASX biotech darling Neuren among sector stocks with upcoming catalysts
2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t... |
Stockhead | NEU | 7 months ago |
The Match Out: Subdued session ahead of 3 key central bank decisions
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.47% to 7196.60. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotif... |
Rask Media | NEU | 7 months ago |
Here are the top 10 ASX 200 shares today
It's been another sad day for the S&P/ASX 200 Index (ASX: XJO) this Tuesday. After the rough start to the trading week the ASX 200 gave us yesterday, investors were probably hoping for a rec... |
Motley Fool | NEU | 7 months ago |
Clinical results for ancient therapy help ASX cannabis stocks weed out competition
Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their cannabinoid products BOD Australia could have the first Schedule 3 CBD product in Australia following positive results from its Phase 2B Ca... |
Stockhead | NEU | 7 months ago |
Selfwealth names top ASX gainers for August; UBS says sell them in September
For me, earnings without guidance is a bit like pizza without cheese – little more than cooked tomato paste on flatbread. And I don’t buy it. Macquarie Bank analysts who know more and are paid better for it, said – in their end of season AS... |
Stockhead | NEU | 7 months ago |
ScoPo’s Powerplays: Should have stayed in bed as ASX stocks fall but Neuren makes S&P ASX 200
ASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Clinuvel down as its European label expansion of SCENESSE knocked back pending further data 2023 biotech market darling elevated to the S&P... |
Stockhead | NEU | 7 months ago |
ASX Rebalance: Biotech Neuren enters S&P ASX 200, Harvey Norman booted and Liontown makes the top 100
Harvey Norman booted out of S&P ASX 100 as lithium play Liontown Resources admitted 2023 market darling of ASX biotech sector Neuren Pharmaceuticals a new addition to S&P ASX 200 The scent of blooming flowers, a gentle warming sun... |
Stockhead | NEU | 7 months ago |
These 6 shares are being kicked out of the ASX 200 index this month
Itâs that time of the year again when S&P Dow Jones Indices announces the rebalance of the S&P/ASX Indices. According to the release, there will be a total of five companies entering the S&P/ASX 200 Index (ASX: XJO) at the n... |
Motley Fool | NEU | 8 months ago |
ScoPo’s Powerplays: ASX health stocks rise as big names ‘trading at very attractive fundamentals’
ASX health sector rises in line with broader markets as reporting season comes to end EBR Systems on schedule for key US FDA submission in Q1 CY24 for (WiSE) CRT system Health imaging company Mach7 achieves record sales order book of $40.3... |
Stockhead | NEU | 8 months ago |
FNArena Corporate Results Monitor – 01-09-2023
Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AGI)) - Ainsworth Game Technology ((ALX)) - Atlas Arteria ((ATA)) - Atturra ((AUA)) - Audeara ((ASB)) - Austal ((BUB)) - Bubs Australia ((CCX))... |
FNArena | NEU | 8 months ago |
3 ASX healthcare stocks that have more than doubled in a year
ASX healthcare stocks haven’t done so well as a collective over the past 12 months. The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 8% over the past year. By comparison, the market benchmark S&P/ASX 200 Index (ASX: XJO) is u... |
Motley Fool | NEU | 8 months ago |
Move over Neuren – Bioshares reckons these ASX health stocks could pop with upcoming key catalysts
Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing... |
Stockhead | NEU | 8 months ago |
MoneyTalks: Why Peak Asset Management is betting on these biotech and lithium plays
MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Peak Asset M... |
Stockhead | NEU | 8 months ago |
MoneyTalks: Merchant Group’s Andrew Chapman has his eye on these diagnostic biotech stocks
MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Today we hear from Andrew Chapman, managing director of Merchant Group Australia. What sector is hot r... |
Stockhead | NEU | 8 months ago |
ScoPo’s Powerplays: ASX health stock fall but hold onto your hat for reporting season
ASX health stocks fall 1.82% in the past five days in line as broader markets rise slightly Resmed sinks after delivering a mixed quarterly result including margins contracting Weight loss drug frenzy drives global big pharma plays Nova No... |
Stockhead | NEU | 8 months ago |
ScoPo’s Powerplays: ASX health stocks rise as Volpara records third quarter of positive cashflow
ASX health stocks up 1% in the past five days in line with broader markets Volpara records third quarter of positive cashflow following successful growth strategy Gut health a popular theme at 17th Bioshares Biotech Summit along with immun... |
Stockhead | NEU | 9 months ago |
ASX Large Caps: Shares higher again as Megaport surges 13pc; mining and energy stocks retreat
ASX 200 climbed to a 100-day high Energy and Mining retreated after a flurry of earnings reports Fortescue Metals fell despite delivering at the top end of guidance Local shares jumped by another 0.75% on Wednesday, touching a 100-day... |
Stockhead | NEU | 9 months ago |
Neuren Pharmaceuticals wins Bioshares Excellence Award
ASX-listed AusBiotech member Neuren Pharmaceuticals (ASX:NEU) has received the Blake Award for Excellence after a successful year, including an FDA approval and key commercial partnerships. |
BiotechDispatch | NEU | 9 months ago |